Docetaxel and cyclophosphamide in patients with advanced solid tumors

ONCOLOGY

Volumn 11, Issue 6 SUPPL., 1997, Pages 21-23

  Valero, Vicente ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SCREENING; FEVER; HUMAN; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS; NEUTROPENIA; PACLITAXEL; TAXOIDS;

EID: 0030813950     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Lavelle F, Bissery MC, Combeau C, et al: Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22(suppl 4):3-16, 1995.
2. Cortes JE, Pazdur R: Docetaxel. / Clin Oncol 13:2643-2655, 1995.
3. 2 as first-line chemotherapy for patients with advanced breast cancer. Report of the Clinical Screening Group of the EORTC. Br J Cancer 74:650-656, 1996.
4. Seidman A, Hudis C, Crown JPA, et al: Phase II evaluation of Taxotere (RP56976, NSC628503) as initial chemotherapy for metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 12:63, 1993.
5. Trudeau ME, Eisenhauer E, Lofters W, et al: Phase II study of Taxotere as first line chemotherapy for metastatic breast cancer (MBC). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Study (abstract). Proc Am Soc Clin Oncol 12:64, 1993.
6. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment for Cancer. J Clin Oncol 13:314-322, 1995.
7. Krakowski I, Rios M, Fumoleau P, et al: Phase II first line chemotherapy (CT) study with docetaxel (Taxotere) and prophylactic premedication of fluid retention (FR) in patients (pts) with metastatic (mts) or locally advanced breast cancer (abstract). Proc Am Soc Clin Oncol 14:97, 1995.
8. Ravdin P, Valero V, Nabholtz JM, et al: Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere induced fluid retention (abstract). Proc Am Soc Clin Oncol 15:115, 1996.